The new era of radio-theranostics in (nuclear) medicine is driven in a significant way by potent radiolabeled PSMA (prostate-specific membrane antigen) inhibitors based on the KuE (lysine-urea-glutamate) motif binding to prostate cancer cells. The gene discussed is FOLH1; the disease is prostate carcinoma.